# Table of Contents

PANEL MEMBERS ............................................................................................................................................................................................................................................... 1
SUMMARY OF THE GUIDELINES UPDATES ................................................................................................................................................................................................. 2
MULTIPLE MYELOMA ....................................................................................................................................................................................................................................... 3
STAGING SYSTEMS FOR MULTIPLE MYELOMA ........................................................................................................................................................................................... 9
DEFINITION OF MULTIPLE MYELOMA (SMOLDERING AND ACTIVE) .................................................................................................................................................... 10
RESPONSE CRITERIA FOR MULTIPLE MYELOMA ..................................................................................................................................................................................... 11
INTERNATIONAL MYELOMA WORKING GROUP UNIFORM RESPONSE CRITERIA1 ............................................................................................................................. 13
MYELOMA THERAPY ....................................................................................................................................................................................................................................... 15
ADJUNCTIVE TREATMENT ............................................................................................................................................................................................................. 17
SYSTEMIC LIGHT CHAIN AMYLOIDOSIS ................................................................................................................................................................................................. 18
NCCN CATEGORIES OF EVIDENCE AND CONSENSUS ................................................................................................................................................................. 20
DISCUSSION ....................................................................................................................................................................................................................................................... 21
Multiple Myeloma
Panel Members
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

NCCN Multiple Myeloma Panel Members

Kenneth C. Anderson, MD/Chair α β *
Dana-Farber/Brigham and Women's Cancer Center

Melissa Alsina, MD β
H. Lee Moffitt Cancer Center & Research Institute

William Bensinger, MD α ξ
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

J. Sybil Biermann, MD λ
University of Michigan Comprehensive Cancer Center

Asher Chanan-Khan, MD α
Roswell Park Cancer Institute

Adam D. Cohen, MD α
Fox Chase Cancer Center

Steven Devine, MD α
The Ohio State University Comprehensive Cancer Center
- James Cancer Hospital and Solove Research Institute

Benjamin Djulbegovic, MD, PhD α β ξ
H. Lee Moffitt Cancer Center & Research Institute

Edward A. Faber, Jr., DO, MS β
UNMC Eppley Cancer Center at The Nebraska Medical Center

Carol Ann Huff, MD α
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Adetola Kassim, MD, MS β ξ
Vanderbilt-Ingram Cancer Center

Gwynn Long, MD α ξ ◊
Duke Cancer Institute

Bruno C. Medeiros, MD β
Stanford Comprehensive Cancer Center

Ruby Meredith, MD, PhD ¥
University of Alabama at Birmingham Comprehensive Cancer Center

Noopur Raje, MD α β
Massachusetts General Hospital Cancer Center

Jeffrey Schrier, MD β ξ
City of Hope Comprehensive Cancer Center

Seema Singhal, MD β
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

George Somlo, MD α β ◊
City of Hope Comprehensive Cancer Center

Keith Stockerl-Goldstein, MD α ξ
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Steven P. Treon, MD, PhD α
Dana-Farber/Brigham and Women's Cancer Center

Guido Tricot, MD, PhD β
Huntsman Cancer Institute at the University of Utah

Donna Weber, MD α β ◊
The University of Texas MD Anderson Cancer Center

Joachim Yahalom, MD ¥
Memorial Sloan-Kettering Cancer Center

Furhan Yunus, MD β
St. Jude Children's Research Hospital/
University of Tennessee Cancer Institute

α Medical oncology
β Hematology
ξ Bone marrow transplantation
λ Surgery/Surgical oncology
¥ Radiotherapy/Radiation oncology
€ Pediatric oncology
◊ Internal medicine
* Writing committee member

NCCN
Rashmi Kumar, PhD
Dorothy A. Shead, MS

NCCN Guidelines Panel Disclosures

Multiple Myeloma

Summary of the Guidelines Updates

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

Summary of the Guidelines Updates

Updates in Version 1.2011 NCCN Multiple Myeloma Guidelines from Version 3.2010 include:

Multiple Myeloma

Initial diagnostic workup  (p. 3)
• Moved serum free light chain assay from useful under some circumstances to initial diagnostic workup.
• Added FISH for 1q21 amplification

Smoldering (asymptomatic) follow-up  (p. 5)
• Changed "Progression to stage II or higher disease" to "Progression to symptomatic myeloma."

Response criteria for multiple myeloma  (p. 11)
• Under time point for assessing response added the following bullet: "Some responses can occur late post-transplant."

Myeloma therapy  (p. 15)
• Bortezomib/cyclophosphamide/dexamethasone combination was added to primary induction therapy for transplant candidates.
• Bortezomib/dexamethasone combination was added to primary induction therapy for nontransplant candidates.
• Melphalan/prednisone/lenalidomide combination was added to primary induction therapy for nontransplant candidates.
• Cyclophosphamide/bortezomib/dexamethasone combination was added to salvage therapy.
• Cyclophosphamide/lenalidomide/dexamethasone combination was added to salvage therapy.
• Footnote 'h' is new to the page: These are representative regimens combining standard agents with novel agents.

Systemic Light Chain Amyloidosis

Primary treatment  (p. 18)
• Added bortezomib with dexamethasone to primary treatment.
• Added cyclophosphamide/thalidomide/dexamethasone combination to primary treatment.
Multiple Myeloma

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

1 Initial Diagnostic Workup

- H&P
- CBC, differential, platelets
- BUN/creatinine, electrolytes
- LDH
- Calcium/albumin
- Beta-2 microglobulin
- 24 h urine total protein
- Serum free light chain assay
- Serum quantitative immunoglobulins, serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (SIFE)
- 24 h urine for total protein, urine protein electrophoresis (UPEP), urine immunofixation electrophoresis (UIFE)
- Skeletal survey
- Unilateral bone marrow aspirate + biopsy, including bone marrow immunohistochemistry and/or bone marrow flow cytometry
- Cytogenetics
- FISH [del 13, del 17, t(4;14), t(11;14), t(14;16), 1q21 amplification]

Useful Under Some Circumstances

- MRI for suspected vertebral compression
- CT scan (avoid contrast)
- PET-CT scan
- Tissue biopsy to diagnose a solitary osseous or extraosseous plasmacytoma
- Bone densitometry
- Plasma cell labeling index
- Staining of marrow and fat pad for amyloid
- Serum viscosity
- HLA typing

2 Clinical Presentation

Solitary plasmacytoma
- See: Primary Treatment for Solitary Osseous and Solitary Extraosseous (p.4)

Smoldering (asymptomatic)
- See: 3 Primary Treatment (p.5)

Active (symptomatic)
- See: 3 Primary Treatment (p.5)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Multiple Myeloma

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

2 Clinical Presentation

Solitary plasmacytoma → Solitary Osseous

Solitary plasmacytoma → Solitary Extraosseous

3 Primary Treatment

RT (≥ 45 Gy) to involved field

RT (≥ 45 Gy) to involved field and/or surgery

4 Follow-up Surveillance After Primary Treatment

• CBC
• Serum chemistry for creatinine, albumin, LDH, calcium, beta-2 microglobulin
• Consider serum free light chain assay
• 24 h urine for total protein, urine protein electrophoresis (UPEP), urine immunofixation electrophoresis (UIFE)
• Serum quantitative immunoglobulins, serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (SIFE)
• Consider bone survey as clinically indicated or annually
• Consider bone marrow biopsy as clinically indicated
• Consider MRI and/or CT and/or PET-CT as clinically indicated or every 6-12 mo

Primary progressive f or
Response followed by progression f

Restage with myeloma workup

See Active (symptomatic) Myeloma

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

See Response Criteria for Multiple Myeloma. (p. 11)
**Multiple Myeloma**

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

### 3 Primary Treatment

**Smoldering/asymptomatic myeloma**
- Observe at 3 - 6 mo intervals (category 1)

**Active/ (symptomatic) myeloma**
- * Induction therapy\(^d\)
- * Bisphosphonates\(^e\) + adjunctive treatment\(^a\) as indicated

### 4 Follow-up Surveillance After Primary Treatment

**Progression to symptomatic myeloma\(^b\)**
- Quantitative immunoglobulins + quantitation of M protein (serum and urine)
- CBC, differential, platelets
- BUN, creatinine, calcium
- Bone survey annually or for symptoms
- Bone marrow biopsy as clinically indicated
- Consider free light chain
- Consider MRI
- Consider PET-CT scan

**Response\(^f\) to induction**
- Harvest stem-cells (adequate for 2 transplants), if candidate for transplantation
  - (Refer for evaluation by stem cell transplant center)

**No response\(^f\) to induction**
- See: 5 Additional Therapy After Response to Induction Therapy (p.6)

**Harvest stem-cells (adequate for 2 transplants), if candidate for transplantation**
- (Refer for evaluation by stem cell transplant center)

\(^a\) See Definition of Multiple Myeloma (Smoldering and Active) (p. 10)
\(^b\) See Myeloma Therapy (p. 15)
\(^d\) See Adjunctive Treatment (p. 17)
\(^e\) See Response Criteria for Multiple Myeloma, (p. 11)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Multiple Myeloma

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

5 Additional Therapy After Response to Induction Therapy

Active (Symptomatic) Myeloma

- Allogeneic\(^9\),\(^h\) stem cell transplant in clinical trial
  - or
- Autologous\(^i\),\(^j\) stem cell transplant (category 1)
  - or
- Continue induction therapy to plateau

6 Follow-up/ Surveillance After Additional Treatment

- Quantitative immunoglobulins + quantitation of M protein at least every 3 mo
- CBC, differential, platelets
- BUN, creatinine, calcium
- Bone survey annually or for symptoms
- Bone marrow biopsy as clinically indicated
- Consider free light chain
- Consider MRI
- Consider PET/CT scan

See Relapse Disease or Progressive Disease (p. 8)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

\(^9\) Allogeneic stem cell transplant may include nonmyeloablative (mini) following autologous stem cell transplant or fully myeloablative on a clinical trial (off-trial category 3). Current data do not support miniallografting alone.

\(^h\) A prospective trial by Bruno, et al. NEJM 2007;356:1110-1120, found improved survival for patients receiving an autologous transplant followed by non-myeloablative allograft compared to patients who received tandem autologous grafts. The IFM trial (99-03) by Garban et al, Blood 2006:107:3474, reported no overall survival or progression free survival with autologous transplant followed by mini allograft in high-risk myeloma patients.


\(^j\) Renal dysfunction and advanced age are not contraindications to transplant.
Multiple Myeloma

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

7 Additional Treatment Post-Stem Cell Transplant

Active (Symptomatic) Myeloma

See: 6 Follow-up/ Surveillance After Additional Treatment (p.6)

Progressive disease

Post allogeneic stem cell transplant

Response or stable disease

Observe or Maintenance therapy

Progressive disease

Salvage therapy on or off clinical trial

or

Donor lymphocyte infusion

Salvage therapy on or off clinical trial

or

Allogeneic stem cell transplant on clinical trial (category 3 for conventional vs clinical trial)

Salvage therapy on or off clinical trial

or

Allogeneic stem cell transplant on clinical trial (category 3 for conventional vs clinical trial)

Salvage therapy on or off clinical trial

or

Donor lymphocyte infusion

Salvage therapy on or off clinical trial

or

Allogeneic stem cell transplant on clinical trial (category 3 for conventional vs clinical trial)

Allogeneic stem cell transplant on clinical trial (category 3 for conventional vs clinical trial)

Additional autologous stem cell transplant on clinical trial (category 2B)

See: 6 Follow-up/ Surveillance After Additional Treatment (p.6)

Progressive disease

Post autologous stem cell transplant

Response or stable disease

Maintenance therapy

or

Second tandem transplant or Observe

Progressive disease

Current data do not support miniallografting alone.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

See Myeloma Therapy, (p. 15)

See Response Criteria for Multiple Myeloma, (p. 11)
Multiple Myeloma

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

8 Relapse Disease or Progressive Disease

Active (Symptomatic) Myeloma

Relapse disease\(^f\) or progressive disease

- Transplant candidate\(^i\)
  - Autologous stem cell transplant (category 1)
  - Progressive disease\(^f\)
    - Salvage therapy\(^d\) on or off clinical trial
    - Additional autologous stem cell transplant on or off clinical trial
    - Allogeneic stem cell transplant on clinical trial\(^g\)

- Non-transplant candidate
  - Salvage therapy\(^d\) on or off clinical trial
  - Palliative care
    - (See NCCN Palliative Care Guidelines)

\(^d\) See Myeloma Therapy, (p. 15)
\(^f\) See Response Criteria for Multiple Myeloma, (p. 11)
\(^g\) Allogeneic stem cell transplant may include nonmyeloablative (mini) following autologous stem cell transplant or fully myeloablative on a clinical trial (off-trial category 3). Current data do not support miniallografting alone.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### Staging Systems for Multiple Myeloma

<table>
<thead>
<tr>
<th>Stage</th>
<th>Durie-Salmon Criteria</th>
<th>ISS Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>All of the Following:</td>
<td>Serum beta-2 microglobulin</td>
</tr>
<tr>
<td></td>
<td>• Hemoglobin value &gt; 10 g/dL</td>
<td>&lt; 3.5 mg/L</td>
</tr>
<tr>
<td></td>
<td>• Serum calcium value normal or ≤ 12 mg/dL</td>
<td>Serum albumin ≥ 3.5 g/dL</td>
</tr>
<tr>
<td></td>
<td>• Bone x-ray, normal bone structure or solitary bone plasmacytoma only</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Low M-component production rate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>→ IgG value &lt; 5 g/dL;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>→ IgA value &lt; 3 g/dL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>→ Bence Jones protein &lt; 4 g/24h</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>Neither stage I nor stage III</td>
<td>Neither stage I nor stage III</td>
</tr>
<tr>
<td>III</td>
<td>One or more of the following:</td>
<td>Serum beta-2 microglobulin</td>
</tr>
<tr>
<td></td>
<td>• Hemoglobin value &lt; 8.5 g/dL</td>
<td>≥ 5.5 mg/L</td>
</tr>
<tr>
<td></td>
<td>• Serum calcium value &gt; 12 mg/dL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Advanced lytic bone lesions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• High M-component production rate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>→ IgG value &gt; 7 g/dL;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>→ IgA value &gt; 5 g/dL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>→ Bence Jones protein &gt; 12 g/24 h</td>
<td></td>
</tr>
</tbody>
</table>

**Subclassification Criteria**

- **A** Normal renal function (serum creatinine level < 2.0 mg/dL)
- **B** Abnormal renal function (serum creatinine level ≥ 2.0 mg/dL)


Multiple Myeloma

Definition of Multiple Myeloma (Smoldering and Active)

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

1 Definition of Multiple Myeloma (Smoldering and Active)

Smoldering (Asymptomatic) Myeloma

M-protein in serum \( \geq 30 \text{ g/L} \)

and/or

Bone marrow clonal plasma cells \( \geq 10\% \)

No related organ or tissue impairment (no end organ damage, including bone lesions) or symptoms.

Active (Symptomatic) Myeloma\(^a\)

Requires one or more of the following:

- Calcium elevation (\( > 11.5 \text{ g/dL} \))
- Renal insufficiency (creatinine > 2 mg/dL)
- Anemia (hemoglobin < 10 g/dL or 2 g/dL < normal)
- Bone disease (lytic or osteopenic)


International Uniform Response

\(^a\) Other examples of active disease include: repeated infections, secondary amyloidosis, hyperviscosity, or hypogammaglobulinemia

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Response Criteria for Multiple Myeloma

EBMT, IBMTR and ABMTR criteria for definition of response, relapse, and progression in patients with multiple myeloma treated by high-dose therapy and stem cell transplant.

Complete response (CR) requires all of the following:

• Absence of the original monoclonal paraprotein in serum and urine by immunofixation, maintained for a minimum of 6 wks. The presence of oligoclonal bands consistent with oligoclonal immune reconstitution does not exclude CR.
• < 5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy, if biopsy is performed. If absence of monoclonal protein is sustained for 6 wks it is not necessary to repeat the bone marrow, except in patients with non-secretory myeloma where the marrow examination must be repeated after an interval of at least 6 wks to confirm CR.
• No increase in size or number of lytic bone lesions (development of a compression fracture does not exclude response).
• Disappearance of soft tissue plasmacytomas.

Patients in whom some, but not all, the criteria for CR are fulfilled are classified as partial response (PR), providing the remaining criteria satisfy the requirements for PR. This includes patients in whom routine electrophoresis is negative but in whom immunofixation has not been performed.

Partial response (PR) requires all of the following:

• ≥ 50% reduction in the level of the serum monoclonal paraprotein, maintained for a minimum of 6 wks.
• Reduction in 24 h urinary light chain excretion either by ≥ 90% or to 200 mg, maintained for a minimum of 6 wks.
• For patients with non-secretory myeloma only, ≥ 50% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy, if biopsy is performed, maintained for a minimum of 6 wks.
• ≥ 50% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination).
• No increase in size or number of lytic bone lesions (development of compression fractures does not exclude response).

Patients in whom some, but not all, the criteria for PR are fulfilled are classified as MR, provided the remaining criteria satisfy the requirements for minimal response (MR).

MR requires all of the following:

• 25-49% reduction in the level of the serum monoclonal paraprotein maintained for a minimum of 6 wks.
• 50-89% reduction in 24 h urinary light chain excretion, which still exceeds 200 mg/24 h, maintained for a minimum of 6 wks.
• For patients with non-secretory myeloma only, 25-49% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy, if biopsy is performed, maintained for a minimum of 6 wks.
• 25-49% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination).
• No increase in size or number of lytic bone lesions (development of compression fractures does not exclude response).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Response Criteria for Multiple Myeloma

No change (NC) - Not meeting the criteria of either minimal response or progressive disease.

Plateau - Stable values (within 25% above or below value at the time response is assessed) maintained for at least 3 mo.

Time point for assessing response:

• Some responses can occur late post-transplant.
• Response to the transplant procedure will be assessed by comparison with results immediately prior to conditioning.
• If transplant is part of a treatment program response to the whole treatment program will be assessed by comparison with the results at the start of the program.

Relapse from CR requires at least one of the following:

• Reappearance of serum or urinary paraprotein on immunofixation or routine electrophoresis, confirmed by at least one further investigation and excluding oligoclonal immune reconstitution.
• ≥ 5% plasma cells in a bone marrow aspirate or on trephine bone biopsy.
• Development of new lytic bone lesions or soft tissue plasmacytomas or definite increase in the size of residual bone lesions (development of a compression fracture does not exclude continued response and may not indicate progression).
• Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.9 mmol/L) not attributable to any other cause.

Progressive disease (for patients not in CR) requires one or more of the following:

• > 25% increase in the level of the serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed by at least one repeated investigation.
• > 25% increase in the 24 h urinary light chain excretion, which must also be an absolute increase of at least 200 mg/24 h and confirmed by at least one repeated investigation.
• > 25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10%.
• Definite increase in the size of existing bone lesions or soft tissue plasmacytomas.
• Development of new bone lesions or soft tissue plasmacytomas (development of a compression fracture does not exclude continued response and may not indicate progression).
• Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.8 mmol/L) not attributable to any other cause.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
## International Myeloma Working Group Uniform Response Criteria

<table>
<thead>
<tr>
<th>Response Category</th>
<th>Response Criteriaa</th>
</tr>
</thead>
<tbody>
<tr>
<td>sCR, stringent complete response</td>
<td>CR as defined below plus: Normal free light chain (FLC) ratio and absence of clonal cells in bone marrowb by immunohistochemistry or immunofluorescencec</td>
</tr>
<tr>
<td>CR, complete response</td>
<td>Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrowb</td>
</tr>
<tr>
<td>VGPR, very good partial response</td>
<td>Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 h</td>
</tr>
<tr>
<td>PR, partial response</td>
<td>≥ 50% reduction of serum M-protein and reduction in 24 h urinary M-protein by ≥ 90% or to &lt; 200 mg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥ 50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥ 30%. In addition to the above listed criteria, if present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required</td>
</tr>
<tr>
<td>SD, stable disease (not recommended for use as an indicator of response; stability of disease is best described by providing the time to progression estimates)</td>
<td>Not meeting criteria for CR, VGPR, PR or progressive disease</td>
</tr>
</tbody>
</table>

---

a All response categories require two consecutive assessments made at anytime before the institution of any new therapy; all categories also require no known evidence of progressive or new bone lesions if radiographic studies were performed. Radiographic studies are not required to satisfy these response requirements.
b Confirmation with repeat bone marrow biopsy not needed.
c Presence/absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is of > 4:1 or < 1:2.
## Multiple Myeloma

### International Myeloma Working Group Uniform Response Criteria

### NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

<table>
<thead>
<tr>
<th>Relapse Subcategory</th>
<th>Relapse Criteria</th>
</tr>
</thead>
</table>
| **Progressive disease**<sup>a</sup> (To be used for calculation of time to progression and progression-free survival and points for all patients including those in CR) (includes primary progressive disease and disease progression on or off therapy) | Progressive Disease: requires any one or more of the following:  
Increase of ≥ 25% from baseline in:  
- Serum M-component and/or (the absolute increase must be ≥ 0.5 g/dL)<sup>b</sup>  
- Urine M-component and/or (the absolute increase must be ≥ 200 mg/24 h)  
- Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels. The absolute increase must be > 10 mg/dL.  
- Bone marrow plasma cell percentage: the absolute % must be ≥ 10%c  
- Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas  
- Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL) that can be attributed solely to the plasma cell proliferative disorder |
| **Clinical relapse**<sup>a</sup> | Clinical relapse requires one or more of:  
Direct indicators of increasing disease and/or end organ dysfunction (CRAB features).<sup>b</sup> It is not used in calculation of time to progression or progression-free survival but is listed here as something that can be reported optionally or for use in clinical practice  
- Development of new soft tissue plasmacytomas or bone lesions  
- Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is defined as a 50% (and at least 1 cm) increase as measured serially by the sum of the products of the cross-diameters of the measurable lesion  
- Hypercalcemia (>11.5 mg/dL)  
- Decrease in hemoglobin of ≥ 2 g/dL  
- Rise in serum creatinine by 2 mg/dL or more |
| **Relapse from CR**<sup>a</sup> (To be used only if the end point studied is DFS, disease free survival)<sup>d</sup> | Any one or more of the following:  
- Reappearance of serum or urine M-protein by immunofixation or electrophoresis  
- Development of ≥ 5% plasma cells in the bone marrow<sup>c</sup>  
- Appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, hypercalcemia) |

---

<sup>a</sup> All relapse categories require two consecutive assessments made at anytime before classification as relapse or disease progression and/or the institution of any new therapy.

<sup>b</sup> For progressive disease, serum M-component increases of ≥1 gm/dL are sufficient to define relapse if starting M-component is ≥5 g/dL.

<sup>c</sup> Relapse from CR has the 5% cutoff versus 10% for other categories of relapse.

<sup>d</sup> For purposes of calculating time to progression and progression-free survival, CR patients should also be evaluated using criteria listed above for progressive disease.

Multiple Myeloma
Myeloma Therapy
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

1 Myeloma Therapy\(^{a,b,c,d}\)

- Exposure to myelotoxic agents (including alkylating agents and nitrosoureas) should be limited to avoid compromising stem-cell reserve prior to stem-cell harvest in patients who may be candidates for transplant.

- Primary induction therapy for transplant candidates:
  - Bortezomib/dexamethasone (category 1)
  - Bortezomib/cyclophosphamide/dexamethasone
  - Bortezomib/doxorubicin/dexamethasone (category 1)
  - Bortezomib/lenalidomide/dexamethasone (category 2B)
  - Bortezomib/thalidomide/dexamethasone (category 1)
  - Dexamethasone (category 2B)
  - Lenalidomide/dexamethasone (category 1)
  - Liposomal doxorubicin/vincristine/dexamethasone (DVD) (category 2B)
  - Thalidomide/dexamethasone (category 2B)

- Primary induction therapy for non-transplant candidates:
  - Bortezomib/dexamethasone
  - Dexamethasone (category 2B)
  - Lenalidomide/low-dose dexamethasone (category 1)
  - Liposomal doxorubicin/vincristine/dexamethasone (DVD) (category 2B)
  - Melphalan/prednisone (MP)
  - Melphalan/prednisone/bortezomib (MPB) (category 1)
  - Melphalan/prednisone/thalidomide (MPT) (category 1)
  - Melphalan/prednisone/lenalidomide (MPL)
  - Thalidomide/dexamethasone (category 2B)
  - Vincristine/doxorubicin/dexamethasone (VAD) (category 2B)

---

\(^{a}\) Selected, but not inclusive of all regimens.
\(^{b}\) Treatments are listed alphabetically and do not imply preference.
\(^{c}\) Recommend herpes zoster prophylaxis for patients treated with bortezomib.
\(^{d}\) Prophylactic anticoagulation recommended for patients receiving thalidomide-based therapy or lenalidomide with dexamethasone.
\(^{e}\) Consider harvesting peripheral blood stem cells prior to prolonged exposure to lenalidomide.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
1 Myeloma Therapy\textsuperscript{a,b,c,d}

- Maintenance therapy:
  \begin{itemize}
  \item Interferon (category 2B)
  \item Lenalidomide\textsuperscript{f}
  \item Steroids (category 2B)
  \item Thalidomide (category 1) ± prednisone (category 2B)
  \end{itemize}

- Salvage:
  \begin{itemize}
  \item Repeat primary induction therapy (if relapse at > 6 mo)
  \item Bendamustine (category 2B)
  \item Bortezomib\textsuperscript{g} (category 1)
  \item Bortezomib/dexamethasone
  \item Bortezomib/lenalidomide/dexamethasone (category 2B)
  \item Bortezomib/liposomal doxorubicin\textsuperscript{g} (category 1)
  \item Cyclophosphamide/VAD
  \item Cyclophosphamide/bortezomib/dexamethasone\textsuperscript{h}
  \item Cyclophosphamide/lenalidomide/dexamethasone\textsuperscript{h}
  \item Dexamethasone
  \item Dexamethasone/cyclophosphamide/etoposide/cisplatin (DCEP)
  \item Dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE)
  \item High-dose cyclophosphamide
  \item Lenalidomide
  \item Thalidomide
  \item Thalidomide/dexamethasone
  \end{itemize}

\textsuperscript{a} Selected, but not inclusive of all regimens.
\textsuperscript{b} Treatments are listed alphabetically and do not imply preference.
\textsuperscript{c} Recommend herpes zoster prophylaxis for patients treated with bortezomib.
\textsuperscript{d} Prophylactic anticoagulation recommended for patients receiving thalidomide-based therapy or lenalidomide with dexamethasone.
\textsuperscript{f} Lenalidomide as maintenance has been evaluated in three independent randomized clinical trials. Results from each of these trials show improvements in TTP. The panel felt that this warranted inclusion; however, this recommendation remains Category 2A since these results have not undergone full peer review and safety/efficacy data are still preliminary.
\textsuperscript{g} Bortezomib/liposomal doxorubicin is preferred to bortezomib single agent.
\textsuperscript{h} These are representative regimens combining standard agents with novel agents.

\textbf{Note:} All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
1 Adjunctive Treatment

Bone Disease

- Bisphosphonates (pamidronate and zoledronic acid)
  - All patients with documented bone disease including osteopenia (category 1)
  - Use of bisphosphonates in smoldering or stage I disease preferably in the context of a clinical trial. These patients should have bone survey yearly
  - Monitor for renal dysfunction with use of bisphosphonates
  - Monitor for osteonecrosis of the jaw
- Radiation Therapy
  - Low-dose radiation therapy (10–30 Gy) can be used as palliative treatment for uncontrolled pain, for impending pathologic fracture or impending cord compression
  - Limited involved fields should be used to limit the impact of irradiation on stem-cell harvest or impact on potential future treatments
  - Orthopedic consultation should be sought for impending or actual long-bone fractures or bony compression of spinal cord or vertebral column instability
  - Consider vertebroplasty or kyphoplasty for symptomatic vertebral compression fractures

Infection (See NCCN Prevention and Treatment of Cancer-Related Infections Guidelines)

- Intravenous immunoglobulin therapy should be considered in the setting of recurrent life-threatening infection
- Consider pneumovax and influenza vaccine
- Consider PCP, herpes, and antifungal prophylaxis if high-dose dexamethasone regimen
- Consider herpes zoster prophylaxis for patients treated with bortezomib

Renal Dysfunction

- Maintain hydration to avoid renal failure
- Avoid use of NSAIDs
- Avoid IV contrast
- Plasmapheresis (category 2B)
- Not a contraindication to transplant
- Monitor for renal dysfunction with chronic use of bisphosphonates

Hyperviscosity

- Plasmapheresis should be used as adjunctive therapy for symptomatic hyperviscosity

Anemia (See NCCN Cancer -and Chemotherapy-Induced Anemia)

- Consider erythropoietin for anemic patients

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### Multiple Myeloma

#### Systemic Light Chain Amyloidosis

**NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011**

1. **Initial Diagnostic Workup**
   
   **Clinical and amyloid-related assessment**
   - Orthostatic vital signs
   - History and physical
   - Abdominal fat pad aspirate or involved organ biopsy
   - Hereditary amyloid testing (for African-American and peripheral neuropathy patients at minimum)

   **Hematologic**
   - CBC with differential
   - Prothrombin time (PT), Partial thromboplastin time (PTT), Factor X (if indicated)

   **Plasma cell disease**
   - Bone marrow aspirate and biopsy with immunohistochemical staining for kappa and lambda and Congo red staining amyloid
   - Electrophoresis of serum and urine
   - Immuno electromicroscopy serum and urine
   - Serum free light chains
   - Blood urea nitrogen, creatinine

   **Renal**
   - 24-hour urinary protein
   - Creatinine clearance

   **Cardiac**
   - EKG
   - Echocardiogram
   - Chest x-ray
   - Brain natriuretic peptide and troponin

   **Liver and GI tract**
   - Alkaline phosphatase, liver enzymes, bilirubin
   - Stool guaiacs
   - Gastric emptying scan (if gastroparesis present)
   - Ultrasound or CT scan to document craniocaudal liver span

   **Peripheral nervous system**
   - EMG (if clinically significant peripheral neuropathy)

   **Other**
   - Endocrine testing: TSH, cortisol
   - Pulmonary testing: Pulmonary function tests

2. **Clinical Findings**

   - **Renal involvement only**
     - Blood urea nitrogen, creatinine
   - **Cardiac involvement**
     - EKG
   - **Multi-organ involvement**

3. **Primary Treatment**

   There are insufficient data to indicate the optimal treatment of amyloidosis and, therefore, all patients should be treated in the context of a clinical trial when possible.

   **Options include:**
   - Best supportive care
   - Bortezomib with or without dexamethasone
   - Dexamethasone and alpha-interferon
   - Cyclophosphamide/thalidomide/dexamethasone
   - Intermediate-dose or high-dose melphalan with stem cell transplant
   - Lenalidomide and dexamethasone
   - Oral melphalan and dexamethasone
   - Thalidomide and dexamethasone

   *Recommend herpes zoster prophylaxis for patients treated with bortezomib.*

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Multiple Myeloma
Systemic Light Chain Amyloidosis
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

Systemic Light Chain Amyloidosis References

NCCN Categories of Evidence and Consensus

**Category 1:** The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus.

**Category 2A:** The recommendation is based on lower-level evidence and there is uniform NCCN consensus.

**Category 2B:** The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).

**Category 3:** The recommendation is based on any level of evidence but reflects major disagreement.

All recommendations are category 2A unless otherwise noted.
Multiple Myeloma

Overview

Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. The American Cancer Society has estimated 20,180 new cancer cases of MM in the United States in 2010, including 11,170 cases in men and 9,010 cases in women, with an estimated 10,650 deaths. The mean age of affected individuals is 62 years for men (75% older than 70 years) and 61 years for women (79% older than 70 years). The treatment of MM has dramatically improved over the past decade. The 5-year survival rate reported in the Surveillance Epidemiology and End Results database has increased from 25% in 1975 to 34% in 2003 owing to newer and more effective treatment options available.

The initial diagnostic workup in all patients should include a history and physical (H&P) examination and the following baseline blood studies: a complete blood count (CBC) with differential and platelet counts; blood urea nitrogen (BUN); serum creatinine and serum electrolytes; serum calcium; albumin; lactate dehydrogenase (LDH); and beta-2 microglobulin. Increased BUN and creatinine indicate decreased kidney function, while LDH levels help assess tumor cell burden in lymphoma-like or plasmablastic myeloma. The level of beta-2 microglobulin reflects the tumor mass and is now considered a standard measure of the tumor burden. Serum analysis also includes quantitative immunoglobulins levels of different types of antibodies (IgG, IgA, and IgM); serum protein electrophoresis (SPEP); and serum immunofixation electrophoresis (SIFE) to obtain more specific information about the type of abnormal antibodies present. Assessing changes and proportions of various proteins, particularly the monoclonal protein (M protein), helps track the progression of myeloma disease and response to treatment. Use of serum free light chain (FLC) assay along with SPEP and SIFE yields high sensitivity while screening for MM and related plasma cell disorders. Therefore, this assay is now included as a part of the initial diagnostic workup in the NCCN Multiple Myeloma Guidelines. The serum FLC assay also has prognostic value in plasma cell disorders, including monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, active myeloma, immunoglobulin light chain amyloidosis and solitary plasmacytoma. The serum FLC assay also allows for quantitative monitoring of patients with light chain amyloidosis and oligosecretory myeloma. However, the FLC assay cannot replace the 24-h urine protein electrophoresis for monitoring myeloma patients with...
measurable urinary M proteins. In addition to all the above, the FLC ratio is required for documenting stringent complete response according to the International Myeloma Working Group Uniform Response Criteria.7

Urine analysis as a part of the initial diagnostic workup includes evaluating 24-hour urine for total protein; urine protein electrophoresis (UPEP) and urine immunofixation electrophoresis (UIFE).

Most patients have serum proteins with or without associated urinary protein. In the Mayo Clinic review of 1027 patients with newly diagnosed with MM, 20% of patients had secretory urinary proteins; however, 3% of patients had neither serum nor urine proteins, and therefore had nonsecretory myeloma.8 Once the myeloma or M-protein is quantified, it is important to use the same test for serial studies to ensure accurate relative quantification.

Other tests carried out as a part of initial diagnostic workup include skeletal survey, unilateral bone marrow aspirate and biopsy. Chromosomal analysis by conventional karyotyping (cytogenetics) and fluorescence in situ hybridization (FISH) may be performed in the plasma cells obtained from bone marrow aspiration. Cytogenetics and FISH may detect chromosomal abnormalities, frequently involving translocations of the immunoglobulin heavy chain genes. Specific chromosomal abnormalities that have been identified include a deletion in chromosome 13 [del(13)] and a translocation between chromosomes 4 and 14 [t(4;14)], both of which are associated with a poor prognosis. A translocation between 11 and 14 [t(11;14)] may be associated with an improved survival.9,10 Other chromosomal abnormalities include deletion in chromosome 17 [del(17)]; translocation between 14 and 16 [t(14;16)]; and amplification of 1q21. At the present time, there are inadequate data to determine how this prognostic information should be used to direct patient management. Also, the adverse impact of these cytogenetic abnormalities has been established in the context of conventional therapies and stem cell transplant but not with novel treatments.

Bone marrow immunohistochemistry may be useful in some cases to confirm presence of monoclonal plasma cells to more accurately measure plasma cell involvement, and bone marrow flow cytometry can help define the disease.

The NCCN Multiple Myeloma panel recommends additional tests that may be useful under some circumstances. These include magnetic resonance imaging (MRI) for suspected vertebral compression,11 computed tomography (CT) or positron emission tomography (PET)/CT scan. Active myeloma is positive on PET scan.12,13 A tissue biopsy may also be necessary to confirm the presence of plasmacytomas.

Plasma cell labeling index may be helpful to identify the fraction of the myeloma cell population that is proliferating.14 Also, staining of bone marrow and fat pad for the presence of amyloid and serum viscosity should be evaluated if hyperviscosity is suspected.

In selected patients with multiple myeloma, physicians may use allogeneic (ie, from someone else) transplantation. In this approach, physicians administer non-myeloablative therapy and infuse stem cells (ie, peripheral blood or bone marrow) obtained from a donor, preferably a Human Leukocyte Antigen (HLA) -identical sibling. In such cases, the patient will need to be HLA-typed.

Finally, since bisphosphonate therapy is a consideration in many patients with multiple myeloma, a baseline bone densitometry test may be recommended.

Diagnostic Categories
Based on the results of the clinical and laboratory evaluation previously discussed, patients are initially classified as either having smoldering...
Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

(asymptomatic) disease or active (symptomatic) disease. Those with active disease are then further categorized according to stage, based on either the Durie-Salmon staging system or the International Staging System (ISS)\(^\text{15}\). The ISS system is based on easily obtained laboratory measures (serum beta-2 -microglobulin and serum albumin) and is easier to use than the Durie-Salmon staging system for patients with previously untreated multiple myeloma.

Response Criteria
Assessing the response to treatment is a key determinant of myeloma treatment. Two different sets of response criteria, one developed by the European Group for Bone and Marrow Transplant (EBMT) and the other developed by the International Myeloma Working Group, are outlined in the NCCN treatment algorithms. The EBMT criteria categorize response as complete response, partial response, minimal response, relapse and progressive disease. In contrast the International Myeloma Working Group criteria categorize response as stringent complete response, complete response, very good partial response, partial response and stable disease. The International Myeloma Working Group criteria have been recently developed, but not yet validated. To date, the EBMT criteria have been more commonly used.

Solitary Plasmacytoma
The diagnosis of solitary plasmacytoma requires a very thorough evaluation to rule out the presence of systemic disease because many patients presumed to have solitary plasmacytomas are found to have occult disease. Solitary plasmacytomas are further categorized as osseous or extraosseous. Osseous plasmacytoma is defined as a plasmacytoma emanating from bone without other evidence of disease. Solitary plasmacytomas derived from soft tissue are termed extraosseous.\(^\text{16}\) However, the treatment and follow-up options for osseous and extraosseous plasmacytomas are similar.

For those patients with osseous plasmacytoma, primary radiation therapy (45 Gy or more) to the involved field is the initial treatment and is potentially curative.\(^\text{17, 18}\) Extraosseous plasmacytomas are treated initially with radiation therapy (45 Gy or more) to the involved field and/or surgery. Follow-up and surveillance for both solitary plasmacytoma and extra-osseous plasmacytoma consist of blood and urine tests done every 4 weeks initially to monitor response to the radiation therapy. If the patient achieves complete disappearance of the paraprotein, then the frequency could be reduced to every 3-6 months and as clinically indicated. If the protein persists, then the monitoring should continue every 4 weeks.

The blood tests include CBC; serum chemistry for creatine, albumin, LDH, calcium, beta-2 microglobulin; serum quantitative immunoglobulins, SPEP, and SIFE. Serum FLC assay may also be considered. The urine tests include 24 hour urine assay for total protein, UPEP, and UIFE.

Bone marrow biopsy should be considered as clinically indicated. Bone survey may be considered annually or as clinically indicated. MRI and/or CT and/or PET/CT may be considered every 6-12 months or as clinically indicated. PET imaging may detect early bone marrow involvement in patients with solitary plasmacytoma.\(^\text{13, 19}\)

If progressive disease emerges, then the patient should be re-evaluated for recurrent extraosseous plasmacytoma or myeloma, and systemic therapy administered as indicated.

Smoldering (Asymptomatic) Myeloma
Patients with asymptomatic smoldering multiple myeloma have an indolent course for many years without therapy. These patients have low concentrations of M-protein (greater than or equal to 30 g/L) and/or bone marrow infiltration greater than or equal to 10% plasma cells; however, they do not have anemia, renal failure, hypercalcemia, or bone lesions. Patients with Durie-Salmon stage I myeloma also have low amounts of
M-protein without significant anemia, hypercalcemia, or bone disease. Patients with smoldering myeloma including Durie-Salmon Stage 1 do not need primary therapy because they can do well for many months to years before the disease progresses. These patients should initially be observed at 3-6 months intervals (category 1 recommendation).

The blood tests include CBC; serum chemistry for creatine, albumin, LDH, calcium, and beta-2 microglobulin; and serum quantitative immunoglobulins, SPEP, and SIFE. Serum FLC assay may also be considered. The urine tests include 24 hour urine assay for total protein, UPEP, and UIFE.

Bone marrow biopsy should be considered as clinically indicated. Bone survey may be considered annually or as clinically indicated. MRI and/or CT and/or PET/CT may be considered as clinically indicated. PET imaging appears to reliably predict active myeloma, by virtue of FDG uptake, low-level smoldering myeloma is consistently negative on the PET scan. It can also assess the extent of active disease, detect extramedullary involvement or evaluate treatment response.

If the disease progresses to stage II or higher, then patients should be treated according to the guidelines for symptomatic MM. Disease progression is defined as a sustained 25% or greater increase in M-protein in serum or urine, greater than 25% increase in plasma cells in bone marrow aspirate or on trephine biopsy, development of new sites of lytic disease, hypercalcemia, or increase size of bone lesions or in tumor volume in plasmacytomas.

Active (Symptomatic) Multiple Myeloma

Induction Chemotherapy

Patients presenting with active (symptomatic) myeloma are initially treated with induction chemotherapy and in selected patients followed by high-dose chemotherapy and autologous stem cell support. Stem cell toxins, such as nitrosoureas or alkylating agents may compromise stem cell reserve and regimens with these agents (notably melphalan) should be avoided in patients who are potential candidates for transplant. Therefore, one of the first steps in evaluating patients with advanced MM is to determine whether or not they would be considered a candidate for high-dose therapy and transplant, based on age and comorbidities. However, it should be noted that advanced age and renal dysfunction are not absolute contraindications to transplant. It is also important to consider supportive care for all patients at the time of diagnosis. For example, 80% of patients have bone disease and up to 33% have renal compromise. Bone disease, renal dysfunction and other complications such as hypercalcemia, hyperviscosity, and coagulation/thrombosis should be treated with appropriate adjunctive measures (see section on Adjunctive Treatment below).

Research into various induction regimens has focused on improving the complete response rates in both transplant and non-transplant candidates.

Primary Induction Therapy for Transplant Candidates

The present choices for induction therapy associated with high-response rates include bortezomib-, lenalidomide-, and thalidomide-containing regimens.

Bortezomib-based regimens

Bortezomib is a first-in-its-class proteasome inhibitor that not only directly targets the myeloma cell, but also targets the interaction between the tumor cell, and the bone marrow microenvironment. For example, apoptotic signaling of the myeloma cells can be triggered in a variety of ways. Bortezomib targets both intrinsic and extrinsic pathways, while dexamethasone targets only the intrinsic pathway. This emerging understanding of the bone marrow microenvironment provides the...
Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

rationale of combining these two drugs.

In the Intergroupe Francophone du Myelome (IFM) cooperative group trial (IFM 2005/01), 482 patients were randomized to either bortezomib and dexamethasone regimen or VAD (vincristine, doxorubicin, and dexamethasone) regimen as induction therapy prior to stem cell transplant. The bortezomib and dexamethasone arm demonstrated a better complete response (CR) rate compared to VAD. Updated results presented at the 2009 Annual Meeting of American Society of Hematology (ASH) confirmed significantly superior post-induction CR/near CR rates in the bortezomib plus dexamethasone arm versus the VAD arm (15% vs. 7%). The rate of achieving very good partial response (VGPR) or better was also higher (39% vs. 16%). Higher response rates post-induction translated to higher rates of progression-free survival (PFS) in bortezomib and dexamethasone arm following high-dose therapy and stem cell transplant. Updated data showed a trend towards prolonged PFS. At a median follow-up of 32.2 months, median PFS was 36 months with bortezomib and dexamethasone versus 29.7 months for VAD. Interestingly, within the bortezomib and dexamethasone group the results showed no significant difference in PFS between patients with ISS Stage III (β2M >5.5) versus Stage I/II (median 29.8 vs. 36.5 months, P = 0.1191), and between patients with versus those without adverse cytogenetics (median PFS of 33.5 vs. 36.5 months, P=0.1655).

Another trial analyzed a large series of patients (younger 65 years) with newly diagnosed MM who were treated with induction therapy of bortezomib and dexamethasone versus VAD before treatment with high-dose melphalan. The results demonstrate that bortezomib improves the prognosis (in terms of both event free survival and OS) of patients with t(4;14), compared with patients treated with VAD induction therapy. Also, bortezomib and dexamethasone induction significantly improved the outcome of patients including those with t(4;14) compared with VAD.

Based on the above data and the uniform consensus among the NCCN myeloma panel members, bortezomib plus dexamethasone is a category 1 option as induction therapy for transplant candidates.

The interim results from the Dutch-Belgian Hemato-Oncology Cooperative Group HOVON-65/ GMMG-HD4 phase III trial of newly diagnosed patients with stage II/III myeloma (n = 300) demonstrated high response rates with the bortezomib, doxorubicin, and dexamethasone (PAD) versus VAD. Post induction response rates with PAD were superior (79% vs. 57%, including CR/near CR of 7% vs. 2% and VGPR or better of 45% vs. 17%). This superior response rate was maintained even after transplant with significantly higher overall response rates (91% vs. 79%, and CR/near CR rates of 26% vs. 14%, and VGPR rates of 71% vs. 44%). No unexpected toxicities occurred, and deletion of chromosome 13q did not have a significant impact on response. Responses improved with bortezomib maintenance. Based on HOVON-65/ GMMG-HD4 trial interim data and the uniform consensus among the NCCN myeloma panel members, bortezomib, doxorubicin, and dexamethasone is a category 1 option for induction therapy for transplant candidates.

The GIMEMA Italian Multiple Myeloma Network reported updated results for a phase III trial investigating bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone induction therapy, followed by tandem autologous SCT with high-dose therapy (melphalan 200 mg/m²), and consolidation therapy with the same induction regimen in 480 myeloma patients. The addition of bortezomib to thalidomide and dexamethasone significantly improved overall response rates both following induction. The first analysis showed superior CR (19% vs. 5%), CR/near CR (26% vs. 9%), and ≥ VGPR (61%
vs. 28%) with bortezomib, thalidomide, and dexamethasone induction. This superiority was retained post-transplant, with higher CR (40% vs. 31%), CR/nCR (52% vs. 41%), and ≥ VGPR (79% vs. 64%) rates, and also post-consolidation. Two-year PFS rates were significantly improved in the bortezomib, thalidomide, and dexamethasone arm (PFS 82% vs. 73%) and 30-month PFS rates were 76% vs. 58%. The superior response with bortezomib, thalidomide, and dexamethasone induction was seen across poor prognostic sub-groups. Patients receiving this induction experienced grade 3/4 peripheral neuropathy; however, response rates remained high for those continuing treatment. A single institution’s retrospective data has reported results similar to the interim data from the GIMEMA trial. The findings of the retrospective analysis demonstrate that with bortezomib, thalidomide, and dexamethasone induction therapy overall response rate seen was 94% of the patients (32 patients out of 34 showed some response, including 56% VGPR or greater). Based on GIMEMA trial data and the uniform consensus among the NCCN myeloma panel members, the addition of bortezomib to thalidomide and dexamethasone is a category 1 option for induction therapy for transplant candidates.

Data from three phase II studies involving 495 patients has demonstrated high response rates with bortezomib, cyclophosphamide, and dexamethasone. The trial by Reeder et al carried out in the U.S. and Canada demonstrated ORR of 88% including a VGPR or greater of 61% and 39% CR/near CR with bortezomib, cyclophosphamide, and dexamethasone induction regimen. In patients who underwent transplantation, the depth of response was maintained post-transplant as well (70% CR/near CR; greater than or equal to VGPR 74%). Analysis of the German DSMM XIa study also demonstrated high responses with bortezomib, cyclophosphamide, and dexamethasone induction regimen (ORR 84%; with 74% partial response (PR) and 10% CR). High response rates were also seen in patients with unfavorable cytogenetics. In the EVOLUTION study, bortezomib, cyclophosphamide, and dexamethasone induction regimen demonstrated ORR of 87% (6% stringent CR; 35% near CR; and 45% PR). Based on data from these three phase II studies, the NCCN panel has now included the combination of bortezomib, cyclophosphamide, and dexamethasone as a category 2A recommendation to the list of options of induction regimens available for transplant candidates.

Phase I/II study results have shown that lenalidomide, bortezomib and dexamethasone is very active and well tolerated in newly diagnosed MM patients. This regimen is included as an induction therapy option for transplant candidates. It is a currently a category 2B recommendation as induction therapy for transplant candidates.

Bortezomib treatment has been associated with an incidence of herpes zoster. The incidence of bortezomib-associated herpes zoster may be reduced with the use of prophylactic acyclovir. The risk of deep vein thrombosis (DVT) is low with bortezomib; however, peripheral neuropathy and gastrointestinal disturbance can be higher. These adverse events are predictable and managed with patient monitoring and appropriate supportive care.

Bortezomib-based regimens may be of value in patients with renal failure and in those with adverse cytogenetic features.

Lenalidomide-based regimen
Lenalidomide, a potent analogue of thalidomide, received FDA approval for the treatment of relapsed/refractory MM in combination with dexamethasone (discussed further below under Salvage Therapy). However, lenalidomide and dexamethasone have been investigated as induction therapy. The Phase III randomized controlled study, S0232, by Southwest Oncology Group (SWOG) compared dexamethasone alone with a combined therapy of dexamethasone plus lenalidomide for patients newly diagnosed with MM. This trial was halted at interim analysis and patients on dexamethasone alone were allowed to switch to lenalidomide with dexamethasone. The SWOG data and safety monitoring committee
Multiple Myeloma

Discussion

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

Based its recommendation to permanently close enrollment based on the preliminary one-year survival results from the Eastern Cooperative Oncology Group (ECOG) phase III study (E4A03).40, 41 At the time the SWOG trial was halted, lenalidomide plus dexamethasone arm showed improved CR rate compared to dexamethasone alone (22% vs. 4%).39

In a recent open-label trial, 445 patients newly diagnosed myeloma were randomly assigned high-dose or low-dose regimens. The response was superior with high-dose dexamethasone. One hundred and sixty nine (79%) of 214 patients receiving high-dose therapy and 142 (68%) of 205 patients on low-dose therapy had complete or partial response within four cycles.42 However, the high response rates did not result in superior time to progression, PFS, or overall survival (OS) compared with low-dose dexamethasone. The trial was stopped after one year and patients on high-dose therapy were allowed crossed over as the overall survival rate was significantly higher in the low-dose arm. At 1-year interim analysis, OS was 96% in the low-dose dexamethasone group compared with 87% in the high-dose group (P = 0.0002); 2- year OS was 87% versus 75% respectively.

The cause of inferior overall survival with high-dose dexamethasone seems to be related to increased deaths due to toxicity. Fifty two percent on the high-dose regimen compared with 35% on the low-dose regimen had grade three or worse toxic effects in the first 4 months, including deep-vein thrombosis (26% vs. 12%); infections including pneumonia (16% vs. 9%); and fatigue (15% vs. 9%). The 3-year OS of patients who received four cycles of induction with either dose followed by autologous stem cell transplantation was 92%, suggesting that lenalidomide plus dexamethasone is reasonable for induction therapy prior to stem cell transplant. Lenalidomide in combination with dexamethasone as induction regimen is a category 1 recommendation in the NCCN guidelines.

A retrospective analysis of 411 newly diagnosed patients treated with either lenalidomide plus dexamethasone (228) or thalidomide plus dexamethasone (183) was performed at the Mayo Clinic.43 In a matched-pair analysis, the differences between the two arms were similar for age, sex, transplantation status, and dexamethasone dose. The proportion of patients achieving at least a partial response to lenalidomide and dexamethasone was 80.3% versus 61.2% with thalidomide and dexamethasone; very good partial response rates were 34.2% and 12.0%, respectively. Patients receiving lenalidomide and dexamethasone had longer time to progression (median, 27.4 vs. 17.2 months; \(P = 0.019\)), longer PFS (median, 26.7 vs. 17.1 months; \(P = 0.036\)), and better OS (median not reached vs. 57.2 months; \(P = 0.018\)). Grade 3 or 4 adverse event (57.5% vs. 54.6%, \(P = .568\)) were seen in similar proportion of patients in both the groups. Main grade 3 or 4 toxicities of lenalidomide and dexamethasone were hematologic, mainly neutropenia (14.6% vs. 0.6%, \(P < 0.001\)); the most common toxicities in thalidomide and dexamethasone were venous thromboembolism (15.3% vs. 9.2%, \(P = 0.058\)) and peripheral neuropathy (10.4% vs. 0.9%, \(P < 0.001\)). Based on the results of this meta-analyses lenalidomide and dexamethasone appears well tolerated and more effective than thalidomide and dexamethasone. However, randomized prospective trials are needed to confirm these results.

A decrease in CD34-positive cells collected after prolonged lenalidomide treatment has been reported.44, 45 Guidelines by the International Myeloma Working Group (IMWG) suggest that patients on lenalidomide in combination with dexamethasone should have stem cells collected within the first 4 cycles of therapy.46 The NCCN panel recommends harvesting peripheral blood early in the courses of induction with lenalidomide.

The incidence of deep vein thrombosis is low with single agent lenalidomide or lenalidomide plus low-dose dexamethasone, but rises when combined with high-dose dexamethasone. According to a recent
Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

Primary Induction Therapy for Non-Transplant Candidates

All of the regimens described above for transplant candidates are also options for non-transplant candidates. The regimens containing melphalan compromise stem cell reserve, and thus are options only for non-transplant candidates.

Thalidomide-based regimen

Thalidomide attacks multiple targets in the microenvironment of the myeloma cell, producing apoptosis, inhibition of angiogenesis and cytokine circuits, among others. Rajkumar et al reported the results of a study involving 207 patients with newly diagnosed multiple myeloma randomized to receive thalidomide and dexamethasone or dexamethasone alone. The response rate to the combined therapy was significantly higher compared to those receiving dexamethasone alone (63% vs. 41%, respectively). Stem cells for subsequent transplant were also successfully collected. However, increased toxicity is associated with thalidomide, specifically DVT; therefore, prophylactic anticoagulation is recommended if thalidomide and dexamethasone are given. Other side effects of thalidomide included rash, gastrointestinal disturbance, peripheral neuropathy, or somnolence. The use of thalidomide requires individual patient consideration and the higher response rate of the thalidomide and dexamethasone combination must be weighed against the increased side effects.

Other regimens

Dexamethasone alone (category 2B recommendation) may be a reasonable option, as short-term induction therapy, for a highly selected group of patients, (eg, in those with renal failure, hypercalcemia, cord compromise requiring radiation therapy, cytopenia). Data from recent studies suggest that VAD no longer be recommended as most patients respond to induction regimen based on novel drug combinations. The other category 2B recommendation is liposomal doxorubicin, vincristine and dexamethasone (DVD) regimen. Melphalan and prednisone (MP) has been a standard treatment of multiple myeloma since 1960. A review of the clinical trials reported that MP results in a 60% response rate with duration of 18 months and an OS of 24 to 36 months. Palumbo and colleagues were the first to report that when thalidomide was combined with melphalan and prednisone (MPT), combined near CR and CR rates were 27.9% for MPT compared to 7.2% for MP. Subsequently, a number of phase III trials have reported significant higher overall response rate with MPT versus MP (57%-76% vs. 31%-48%), including a higher CR or VGPR rate (7%-15.5%). The impact of MPT on survival is not clear as only the IFM studies have reported a survival advantage in patients on MPT. The Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) carried out a phase III study to compare the standard MP versus MPT in 333 newly diagnosed elderly patients with MM. Significantly higher responses rates were seen with MPT treated patients compared to MP and were comparable with response rates seen in the French and Italian trial described above. Overall response rate with MPT (CR+VGPR+PR) was 66% versus 45% with MP. The number of patients not responding to therapy or patients with progressive disease was 55% with MP and 34% with MPT. The EFS was 13 months with MPT versus 9 months with MP and OS was 40 months with MPT versus 31 months with MP. Comparisons between these studies are difficult because of differences in patient populations, duration of treatment and use of maintenance regimens.

Due to the significantly higher overall response rates consistently seen in all these studies, MPT is a category 1 recommendation for patients not eligible for transplant. There is a significant risk of DVT with thalidomide;
Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

therefore, use of prophylaxis in patients on MPT therapy is highly recommended.

Addition of bortezomib to MP (MPB) was investigated in a large randomized international phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial. The trial evaluated MP (n = 338) versus MPB (n = 344) in previously untreated patients with MM who were 65 years of age or older, or patients younger than 65 years of age and transplant ineligible. The addition of bortezomib resulted in highly significant increases in time to disease progression, PFS, OS, time to next treatment, and complete response. Importantly, adverse cytogenetics, advanced age, and renal function had no impact on the efficacy of the bortezomib-containing regimen, which was well tolerated.

Updated results from the phase III VISTA trial with a median follow-up of 36.7 months show a 35% reduced risk of death with MPB versus MP. The 3-year OS rate was 68.5% in the MPB arm compared to 54% in the MP arm. With MPB, time to progression and OS were unaffected by advanced age, renal impairment, and adverse cytogenetics ([t(4;14), t(14;16), del(17p)]). The adverse events were higher in the MPB arm; however, discontinuation of treatment due to adverse events was reported to be similar in both arms. Improvement in peripheral neuropathy in patients treated with MPB was seen within a median of 1.9 months; 60% completely resolved within a median of 5.7 months.

Another interesting finding from this study was that patients relapsing after bortezomib-based therapy are not more resistant to subsequent therapies and can be as successfully treated with subsequent immunomodulatory drug-based therapies. The median survival from start of subsequent therapy was 30.2 months for those treated initially with MPB versus 21.9 months for those with MP. Response rates to second-line bortezomib-, thalidomide-, and lenalidomide-based therapies were 41%, 37%, and 73%, respectively after MPB, and 59%, 47%, and 67%, respectively, after MP. This finding supports the strategy of using bortezomib-based treatment as first-line therapy instead of reserving it as salvage after upfront conventional therapy. Based on the VISTA trial results, the MPB regimen is now a NCCN category 1 recommendation.

Advantages of MPB over MPT include more rapid response and higher rates of CR, which is associated with improved survival in the non-transplant setting. Results of VISTA also support use of MPB in patients with high-risk cytogenetics and/or impaired renal function. There is no randomized head-to-head study comparing MPT and MPB; however, a meta-analysis of the phase III studies has demonstrated that better response rates could be expected with MPB than with MPT. Yeh et al compared the existing data (on MP, MPT, and MPB) and calculated an 81% probability that MPB was the most efficacious among the three regimens in terms of overall response rates and a greater than 99% probability that it was also the most efficacious in terms of CR. No difference was seen in OS and PFS between MPB and MPT regimens.

Both MPT and MPB regimens have reported superior responses compared to MP; therefore, according to the NCCN myeloma panel, MP is a category 2A recommendation. Based on the results of the SWOG SO232 trial, which included non-transplant candidates and the results of ECOG E4A03 trial which included elderly patients as well, lenalidomide in combination with low dose dexamethasone is a well tolerated and effective regimen for elderly. In the study (discussed in the previous section) the OS rate was significantly higher in the lenalidomide plus low-dose arm compared to lenalidomide plus high-dose dexamethasone arm. The inferior survival outcome seen with high-dose dexamethasone was greatest in patients 65 years and older. At 2 years, patients who did not proceed to transplant had an OSI of 91% with lenalidomide and low-dose dexamethasone. Therefore, lenalidomide in combination with low-dose dexamethasone considered a category 1 option by the NCCN panel for non-transplant candidates. The panel recommends appropriate
Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

thromboprophylaxis for patients receiving this therapy.

Melphalan and prednisone in combination with lenalidomide (MPL) was studied in 54 patients with newly diagnosed MM. Although there were concerns about myelosuppression with lenalidomide, therapy with oral MPL produced very high response rates. Eighty one percent of patients achieved at least a partial response, 47.6% achieved a very good partial response, and 24% achieved a complete immunofixation-negative response. One year event-free survival in all patients was 92% and OS was 100%. Common grade 3/4 toxicities seen were neutropenia (in 52%), thrombocytopenia (in 24%), and anemia (in 5%).

A subsequent analysis of the kinetics of neutropenia and thrombocytopenia as well as the safety and efficacy of MPL showed that the hematologic toxicities are manageable, median PFS was 28.5 months, and 2-year OS was 91%. The investigators suspect that cytotoxicity of bone marrow is related to melphalan in the regimen.

In another phase I/II trial of newly diagnosed MM patients not eligible for autologous SCT (median age 74 years), MPL regimen showed substantial activity (CR was 12%, ORR was 69%) with a manageable toxicity profile. The most common grade 3/4 toxicities were neutropenia (58% of patients) and thrombocytopenia (27%).

The phase III MM-015 study is evaluating 459 patients (median age 65) with newly diagnosed MM randomly assigned to MPL followed by lenalidomide maintenance or MPL followed by placebo maintenance, or MP followed by placebo maintenance. At a preplanned interim analysis the data monitoring committee detected a highly statistically significant improvement in PFS, the primary endpoint, for patients treated with MPL followed by lenalidomide maintenance compared with those who received MP. The MPL regimen is now included as an option for patients ineligible for transplant in the updated NCCN Myeloma guidelines. It is a category 2A recommendation.

Among the bortezomib-based regimens, MPB has been investigated specifically in elderly patients in the phase III VISTA trial. A U.S. community-based, randomized, open-label, multicenter phase IIIb UPFRONT trial, is comparing safety and efficacy of three highly active bortezomib-based regimens. Bortezomib in combination with thalidomide and dexamethasone; bortezomib with dexamethasone; and MPB are being compared with each other in previously untreated elderly patients with MM ineligible SCT. The interim results demonstrate that all three regimens are active with good response rates with predictable and similar rates of toxicities reported for all arms. The NCCN panel has now included bortezomib in combination with dexamethasone as an option for patients ineligible for transplant (category 2A). The older regimens like dexamethasone alone, thalidomide with dexamethasone, VAD, and DVD regimens are category 2B options.

Follow-Up after Induction Therapy
Following initial induction chemotherapy, patients are re-evaluated with the laboratory tests, bone survey and bone marrow biopsy to determine whether there has been a treatment response, or whether primary progressive disease is present. Potential transplant candidates undergo a stem cell harvest, collecting enough stem cells for two transplants in anticipation of a tandem transplant or a second transplant as salvage therapy. Autologous and allogeneic transplants are discussed further below. Alternatively, all patients may consider continuation of induction therapy to reach a treatment plateau. Treatment should be continued for, at most, two cycles beyond maximal response; continued treatment does not prolong the duration of the plateau phase.

Stem Cell Transplants
Introduction
High-dose chemotherapy and stem cell transplants (SCT) can be classified as a single autologous SCT, a tandem SCT, or an allogeneic SCT. An allogeneic SCT can be either done after prior myeloablative...
therapy, or after nonmyeloablative therapy. Nonmyeloablative therapy, also referred to as “mini transplant” has been investigated as a technique to decrease toxicity of the allotransplant while preserving the alloimmune graft-versus-myeloma effect. An allogeneic SCT may also follow an autologous SCT. The NCCN guidelines indicate that all types of SCT are appropriate in different clinical settings; these indications are discussed further below. However, in general, all candidates for high-dose chemotherapy must have sufficient liver, renal, pulmonary, and cardiac function. Earlier studies of autologous transplant included total body irradiation (TBI) as component of the preparative regimen. Regimens with chemotherapy only have recently been shown to have equivalent efficacy and less toxicity than TBI, and TBI regimens have now been abandoned.

**Autologous Stem Cell Transplants**

Autologous SCT results in high response rates and remains the standard of care following induction therapy for eligible patients. In 1996, results of the first randomized trial were reported; this trial demonstrated that autologous SCT is associated with statistically significant higher response rates as well as increased overall and event-free survival when compared with the response of similar patients treated with conventional therapy. In 2003, results of a second trial comparing high-dose therapy to standard therapy showed an increase in the complete response rate and an improvement in overall survival (54 months in the high-dose group compared to 42 months for standard therapy). The benefit was more pronounced for higher risk patients. Barlogie and colleagues reported on the results of an American trial that randomized 510 patients to receive high-dose therapy with autologous stem cell support or standard therapy. With a median follow-up of 76 months, there were no differences in response rates, PFS, or OS between the two groups. The reason for the discrepant results are not clear, but may be related to differences in the specific high dose and conventional regimens between the American and French study. For example, the American study included TBI as part of the high dose regimen; TBI has subsequently been found to be inferior to high-dose melphalan.

Another trial included 190 patients aged 55 to 65 randomized to standard or high-dose therapy. This study was specifically designed to include older patients, since the median age of the participants in other trials ranged from 54-57 years while the median age in this trial was 61 years. After 120 months of follow-up, there was no significant difference in OS, although there was a trend toward improved event-free survival in the high-dose group ($P = 0.7$). Additionally, the period of time without symptoms of treatment or treatment toxicity (TWiSTTs) was significantly longer in the high dose group. The study concluded that the equivalent survival suggests that the treatment choice between high-dose and conventional dose chemotherapy should be based on personal choice in older patients. For example, an early transplant may be favored because patients can enjoy a longer interval of symptom-free time. However, this study also showed that a transplant performed at the time of relapse (as salvage therapy) has a similar OS compared to an early transplant.

It should be noted that all randomized studies of autologous SCT following induction therapy were designed and implemented prior to the availability of thalidomide, lenalidomide or bortezomib. Therefore, the role of transplant may evolve in the future. Results from the IFM 2005/01 study of patients with symptomatic myeloma receiving induction therapy with either bortezomib/dexamethasone versus VAD showed a marked improvement in overall response rate with bortezomib/dexamethasone over VAD (discussed in sections above). After the first autologous SCT, CR/near CR rates were 40% in the bortezomib plus dexamethasone arm, compared with 22% in the VAD arm ($P = 0.0001$). In the bortezomib plus dexamethasone arm 34% required a second SCT, compared with 47% of patients in the VAD arm. With a median follow-up of 32.2 months, PFS after induction with bortezomib and dexamethasone versus VAD group was 36.0 and 29.7 months, respectively.
evaluated post-induction and post-autologous SCT. Progression free survival was significantly longer in patients achieving greater than or equal to a VGPR after autologous SCT than in the 188 patients achieving less than VGPR (median 41.1 vs. 33.5 months). Also, PFS was also significantly longer in the patients achieving greater than or equal to a VGPR after induction than in patients achieving a less than VGPR (median 41.1 vs. 29.0 months).24

In another study, bortezomib/dexamethasone with thalidomide was compared with thalidomide/dexamethasone for induction therapy prior to SCT in 450 patients.27 The three drug yielded high response rates compared with the two drug regimen, with CR/near CR of 32% (vs. 12%) and VGPR of 62% (vs. 29%). After SCT, improved responses were still seen with bortezomib, dexamethasone, and thalidomide compared with thalidomide plus dexamethasone (CR/near CR 55% vs. 29%; VGPR, 76% vs. 53%). Taken together these studies suggest that improved responses with the new induction regimen result in improved outcomes after transplantation.72 Studies have found that progressive disease emerging after initial induction chemotherapy does not preclude a good response to autologous SCT.70, 73, 74 For example, Kumar and colleagues reported on a case series of 50 patients with primary progressive multiple myeloma receiving an autologous SCT.74 Results were compared to 100 patients with responsive disease undergoing autologous SCT. The one year PFS from the time of transplant was 70% in the primary progressive group compared to 83% in the chemosensitive group. For this reason, the guidelines indicate autologous SCT as a category 1 option for treatment of primary progressive or refractory disease post induction treatment.

Tandem Stem Cell Transplants

Tandem SCT refers to a planned second course of high-dose therapy and SCT within 6 months of the first. Planned tandem transplants have been studied in several randomized trials. The IFM94 trial reported by Attal et al randomized newly diagnosed myeloma patients to single or tandem autologous transplants.75 A total of 78% of patients assigned to the tandem transplant group received the second transplant at a median time of 2.5 months after the first. A variety of options for salvage therapy were provided. For example relapsing patients in either group underwent either no therapy, additional conventional therapy or another stem cell transplant. The probability of surviving event free for seven years after the diagnosis was 10% in the single transplant group compared to 20% in the double transplant group. An accompanying editorial by Stadtmauer questions whether the promising results might be related to regimens used, rather than the effect of two courses of high-dose therapy.76 For example, patients in the single transplant arm received 140 mg/m² melphalan plus TBI, while those in the tandem arm received the same dose without TBI for the initial transplant and with TBI for the second transplant. As noted above, TBI has been shown to be more toxic without providing additional benefit. Based on this, the editorial suggests that the increased survival in IFM94’s tandem arm may have resulted from greater cumulative exposure to melphalan (280 vs. 140 mg/m²). In a subset analysis, those patients who did not achieve a complete CR or a VGPR within 3 months after the first transplant appeared to benefit the most from a second transplant. The authors of the IFM94 study have suggested that the improvement in projected survival associated with tandem transplant is related not to improved response rates, but to longer durations of response. Four other randomized trials have compared single versus tandem transplant.71, 77-79 None of these trials showed a significant improvement in OS. However, since the median follow-up in these trials ranged from 42 to 53 months, the lack of significant improvement is not surprising. The Cavo trial77 found that patients not in CR or near CR after the first transplant benefited the most from a second transplant. This confirms the observations of the IFM94 trial using non-TBI based high-dose regimens.

In both the French and Italian trials, the benefit of a second autologous SCT was seen in patients failing to achieve a complete response or
very good partial response (greater than 90% reduction in M protein level) with the first procedure. These two studies were not adequately powered to evaluate the equivalence of one versus two transplants in patients achieving a CR or VGPR after the first transplantation.

A review of long-term outcomes of several trials of autologous transplantation by Barlogie et al found that tandem transplantations were superior to both single transplantations and standard therapies. Also, post relapse survival was longer when event-free survival was sustained for at least 3.5 years after tandem transplantation.

The NCCN Myeloma panel recommends collecting enough stem cells for two transplants in all eligible patients. According to the NCCN Multiple Myeloma panel, a tandem transplant can be considered for all patients who are candidates for SCT, and is an option for patients who do not achieve at least a VGPR after the first autologous SCT. The benefit from the second transplant in patients who are in CR, or VGPR, and also in those who achieve less than VGPR after the first SCT, should preferably be answered in a clinical trial. In fact, such a randomized prospective NIH and Intergroup-supported trial is currently ongoing. The other options for this group of patients include maintenance therapy or observation.

The algorithms also identify two situations where a repeat salvage autologous SCT is recommended: 1) In patients initially treated with induction therapy alone, followed by an autologous SCT when the disease relapsed, who now have progressive disease following a first autologous SCT (category 2A); and 2) In patients with initial CR or near CR to an initial single autologous SCT who develop progressive disease. There are less data on this population of patients compared to autologous SCT for responsive or primary progressive disease, in part due to the age of the patients and extensive prior treatment. However, a systemic review sponsored by the American Society for Blood and Marrow Transplant (ASBMT) regarding this population reported that some of these patients can achieve durable complete or partial remission. For this reason it is a category 2B recommendation and participation in a clinical trial is encouraged.

Allogeneic Stem Cell Transplant

Allogeneic SCT includes either myeloablative or nonmyeloablative (i.e. “mini” transplant) transplants. Allogeneic SCT has been investigated as an alternative to autologous SCT both to avoid the contamination of re-infused autologous tumor cells, but also to take advantage of the beneficial graft versus tumor effect associated with allogeneic transplantations. However, the lack of a suitable donor and the increased morbidity have limited this approach, particularly for the typical older MM population. Non-myeloablative transplants are designed to decrease the morbidity of the high-dose chemotherapy but preserve the beneficial graft versus tumor effect. Therefore, the principle difference between myeloablative and nonmyeloablative transplants relates to the chemotherapy regimen used. Specific preparatory regimens have not been a focus of the NCCN guidelines, and therefore these guidelines do not make a distinction between these approaches.

Given the small candidate pool, it is not surprising that there have been no randomized clinical trials comparing myeloablative allogeneic to autologous SCT, but multiple case series have been published describing allogeneic SCT as an initial or salvage therapy for multiple myeloma. In a 1999 review, Kyle reported a mortality rate of 25% within 100 days and overall transplant-related mortality of approximately 40% and few patients were cured. Other reviews have also reported increased morbidity without convincing proof of improved survival. There are, however, intriguing data from the SWOG randomized trial of autologous transplant versus conventional chemotherapy. The original trial had an ablative, allogeneic transplant group in which patients with HLA identical siblings were assigned. Only 36 patients received allografts, and because of the high 6-month mortality of 45% the allogeneic arm was closed. With seven
years of follow-up the overall survival of the conventional chemotherapy, autologous and allogeneic arms are all identical at 39%. The autologous and conventional chemotherapy arms do not demonstrate a plateau, however, while the allogenic curve is flat at 39%. This suggests that a proportion of these patients are long-term survivors. Thus, there is ongoing interest in myeloablative allogeneic SCT, particularly given that lack of a significant cure rate for single or tandem autologous-SCT. Therefore, the NCCN guidelines consider myeloablative SCT an accepted option in the setting of a clinical trial (category 2A) in patients with responsive or primary progressive disease, or as salvage therapy in patients with progressive disease following an initial autologous-SCT.

Another strategy that has been investigated is an initial autologous-SCT followed by a mini-allogeneic transplant. A prospective trial by Bruno et al.\(^8\) showed that, among patients (under 65 years) with a HLA-matched siblings who received an autograft-allograft regimen, CR rate after allografting was 55%, compared with 26% after double autograft in patients without HLA-matched siblings. Median OS was higher (80 vs. 54 months). In contrast, in a comparison of tandem autologous-SCT versus those treated with an initial autologous-SCT followed by a mini-allogeneic transplant in high-risk patients in the IFM99-03 and IFM 99-04 studies\(^8\) the OS and the event free survival were not significantly different for the two groups.

Mini-allogeneic transplants have also been investigated as salvage therapy. In a case series report, 54 patients with previously treated relapsed or progressive disease were treated with an autologous-SCT followed by a mini-allogeneic transplant.\(^8\) There was a 78% OS at a median 552 days after the mini-allogeneic transplant, with a 57% complete response rate and an overall response rate of 83%. This study concluded that this approach reduced the acute toxicities of a myeloablative allogeneic-SCT while preserving anti-tumor activity. The largest case series was reported by the EBMT.\(^8\) In this heterogeneous population of 229 patients, the 3-year overall and progression free survivals were 41% and 21%, respectively. Adverse overall survival was associated with chemoresistant disease, more than 1 prior transplant, and improved overall survival was associated with graft versus host disease, confirming the importance of a graft versus leukemia effect. This study concluded that mini-allogeneic transplantation is feasible, but heavily pretreated patients and patients with progressive disease are unlikely to benefit.

Patients whose disease either does not respond to or relapses after allogeneic stem cell grafting may receive donor lymphocyte infusions in order to stimulate a beneficial graft-versus-myeloma effect.\(^8\)

**Maintenance Therapy Following Transplant**

A variety of maintenance therapies, such as dexamethasone and interferon, have been investigated in patients whose disease responds to high-dose therapy with autologous or allogeneic SCT.\(^8\) At the present time, the role of interferon\(^8\) or steroid maintenance therapy\(^9\) in general is uncertain, and for this reason these are category 2B recommendations as maintenance therapy.

Thalidomide as maintenance therapy after a prior autologous-SCT has been studied in retrospective as well as independent randomized trials. In a retrospective review of 112 patients undergoing autologous-SCT, Brinker and colleagues reported on the outcomes of 36 patients who received thalidomide as maintenance or salvage therapy compared to 76 patients who received no post-transplant therapy.\(^9\) The median survival in the thalidomide group was 65.5 months compared to 44.5 months in the no treatment group (\(P = 0.9\)). Attal et al. randomized 597 patients to one of three different strategies following tandem autologous stem cell transplantation, either no maintenance, pamidronate alone, or pamidronate combined with thalidomide.\(^9\) There was a highly significant event free and overall survival advantage in the thalidomide and
Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

pamidronate arm. The group that appeared to benefit the most was one that had patients who achieved only a partial response after transplantation. However, peripheral neuropathy is a challenge with low-dose thalidomide, and may preclude long-term maintenance. An Australian study compared thalidomide plus prednisone versus prednisone alone. The results confirm that thalidomide added to maintenance is superior to prednisone alone.93 In another randomized trial, thalidomide maintenance induced improvement in PFS in patients achieving less than a VGPR with no survival benefit.94 Thalidomide has also been used before, during, and after tandem autologous SCT.70, 95 In a randomized study of 668 newly diagnosed patients, half received thalidomide throughout the course of the tandem autologous-SCT, i.e. thalidomide was incorporated into induction therapy, continued between the tandem autologous-SCTs, and was incorporated into consolidation therapy and continued as maintenance therapy.95 The “no thalidomide” group received the same core therapy. After a median follow-up of 42 months, the thalidomide group had improved complete response rates (62% vs. 43%) and five-year event-free survival rates (56% vs. 44%). However, the OS rate was approximately 65% in both groups. Patients who did not receive thalidomide throughout therapy benefited from thalidomide at the time of relapse. The results of this study suggest that sequencing drugs may be important. For example, if thalidomide is used as part of up front therapy, another drug should be considered for maintenance therapy.

Based on the above evidence, according to the NCCN panel thalidomide alone is a category 1 recommendation and thalidomide with prednisone is a category 2A recommendation as maintenance therapy.

Lenalidomide as maintenance is being evaluated in three independent randomized phase III studies. The CALGB 100104 trial compared lenalidomide versus placebo as maintenance therapy after prior autologous stem cell transplant.96 The preliminary results show that patients receiving lenalidomide maintenance following a autologous stem cell transplant had a 58% reduction in risk of their disease progressing.97 These encouraging results have led to un-blinding of this trial.

Preliminary data from the international, randomized, double-blind phase III Intergroupe Francophone du Myelome (IFM) 2005-02 trial98 show that following autologous stem cell transplant, patients treated with lenalidomide as consolidation therapy followed by lenalidomide as maintenance therapy had upgraded responses. The benefit of lenalidomide maintenance therapy was observed both among patients achieving or not a complete response after autologous SCT. Data from a pre-planned interim analysis show improved progression-free survival in patients receiving lenalidomide consolidation and maintenance compared to those who received placebo.99

Data from the Phase III MM-015 study shows that lenalidomide reduced the risk of disease progression by 47%. Analysis of PFS after cycle 9 of induction therapy shows that patients receiving lenalidomide as maintenance therapy had a 75% reduction in disease progression compared with those on placebo following induction.63

Based on the above evidence the NCCN Myeloma Panel recommends single agent lenalidomide as maintenance therapy. However, pending peer reviewed publications of the above mentioned phase III trial results and the safety/efficacy data of lenalidomide in this setting, the current NCCN category of evidence and consensus for recommending lenalidomide as maintenance therapy is category 2A.

Bortezomib as maintenance therapy is currently under investigation100, 101 and according to the NCCN Multiple Myeloma panel the currently available data are premature to recommend bortezomib in this setting.
Salvage Therapy

Conventional dose salvage therapy is considered in the following clinical situations: for patients with relapsed disease following allogeneic or autologous SCT; for patients with primary progressive disease following initial autologous or allogeneic SCT; for patients ineligible for stem cell transplant with progressive or relapsing disease after initial induction therapy.

A variety of therapies are available as options for salvage therapy. If the relapse occurs at greater than 6 months after completion of the initial induction therapy, patients may be retreated with the same induction regimen. Bortezomib is considered a category 1 recommendation for salvage therapy based on the results of a phase III trial (APEX trial) comparing bortezomib and high-dose dexamethasone as salvage therapy. Among the 669 participants, patients randomized to bortezomib had a combined complete and partial response rate of 38% compared to 18% for those receiving dexamethasone, improved median time to progression (6.22 vs. 3.49 months) and one-year survival (80% vs. 66%). When combined with dexamethasone, bortezomib is considered a category 2A recommendation. In an updated efficacy analysis, the response rate was 43% with bortezomib versus 18% for dexamethasone ($P < 0.0001$). A CR or near CR was observed in 16% versus 0% of relapsed patients, respectively. Median OS was 29.8 months with bortezomib and 23.7 months with dexamethasone, despite nearly two thirds of patients crossing over to bortezomib. One-year survival rates were 80% and 67%, respectively ($P = 0.00002$). Patients with poor prognostic factors also benefited from bortezomib. Deletion of chromosome 13 did make a difference in patients treated with dexamethasone, as it was associated with worse survival, but it had no impact in bortezomib-treated patients.

Regimen for combining bortezomib with pegylated liposomal doxorubicin (PLD) injection is a treatment option for multiple myeloma in patients who have not previously received bortezomib and have received at least 1 prior therapy. The FDA approval of this regimen was based on a priority review of data from an international phase III trial (n = 646), showing that use of the drug combination significantly extended the median time to disease progression compared with bortezomib alone (9.3 vs. 6.5 months). Median duration of response was increased from 7.0 months to 12.0 months with the combination therapy. The most commonly reported grade 3 or 4 adverse reactions associated with use of doxorubicin liposome and bortezomib were neutropenia (32%), thrombocytopenia (24%), anemia (9%), fatigue (7%), anemia (6%), diarrhea (7%), peripheral neuropathy (7%), and hand-foot syndrome (6%). Other commonly reported events (any grade) were pyrexia (31%), nausea (48%), vomiting (32%), constipation (31%), stomatitis (20%), and rash (22%).

Lenalidomide combined with dexamethasone has received FDA approval based on the results of two studies of 692 patients with multiple myeloma who had received at least one prior treatment and were randomized to receive either dexamethasone with or without lenalidomide. The primary efficacy endpoint in both studies was time to progression. A pre-planned interim analysis of both studies reported that the median time to progression was significantly longer in the lenalidomide arm compared to the control group. The updated clinical data from the pivotal North American Phase III trial (MM-009) in 353 previously treated multiple myeloma patients reported increased overall survival, as well as median time to disease progression in patients receiving lenalidomide plus dexamethasone compared to patients receiving dexamethasone plus placebo. Similar results were also shown in the trial from the international study MM-010. Patients in both these trials had been heavily treated prior to enrollment, many having failed three or more rounds of therapy with...
Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

other agents. In addition, more than 50 percent of patients in the study had undergone stem cell transplantation. Most adverse events and Grade 3/4 adverse events were more frequent in multiple myeloma patients who received the combination of (lenalidomide/ dexamethasone compared to placebo and dexamethasone. Thrombocytopenia (61.5%) and neutropenia (58.8%) were the most frequently reported adverse events observed. The NCCN panel now considers this regimen as a category 1 recommendation.

Lenalidomide monotherapy has also been investigated and is also a category 2A recommendation.

Thalidomide has also been investigated as a salvage therapy either as monotherapy or in combination with a variety of agents, including dexamethasone or in combination with dexamethasone, cisplatin, doxorubicin cyclophosphamide and etoposide (DT-PACE). Thalidomide has been shown to induce responses in 30% of patients with progressive myeloma. In another study of 65 patients with relapsed or progressive disease, 34% had minor (14%), partial (14%) or complete (6%) response; response was noted by 3 to 5 weeks of treatment. Other salvage regimens, all considered category 2A, include, cyclophosphamide-VAD (C-VAD); high-dose (non-marrow ablative) cyclophosphamide, dexamethasone; and DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin)

The addition of an alkylating agent (such as cyclophosphamide) to dexamethasone and a novel agent (such as lenalidomide or bortezomib) are being investigated. A retrospective analysis to assess the efficacy of lenalidomide in combination with cyclophosphamide and dexamethasone showed that this regimen is effective in heavily pre-treated patients with manageable side-effects. A phase I/II study of cyclophosphamide and prednisone in combination with bortezomib in 37 relapsed/refractory MM patients demonstrated overall response rate of 95% with CR seen in over 50% of the patients. The NCCN myeloma panel has added cyclophosphamide and dexamethasone in combination with either lenalidomide or bortezomib for relapsed/refractory myeloma.

In a trial by Knop and colleagues, 31 patients who had experienced relapse after high-dose chemotherapy and autologous transplantation were enrolled to receive increasing doses of bendamustine. The overall response rate was 55% with a median progression-free survival of 26 weeks for all patients and 36 weeks for patients who received higher doses of bendamustine (90-100 mg/m²). Toxicity was mild and mainly hematologic. A retrospective analysis of 39 patients has suggests that bendamustine is effective and tolerable in patients with advanced progressive myeloma. The overall response rate seen in the analyses was 36%. Bendamustine for treatment of relapsed/refractory myeloma is currently a NCCN category 2B recommendation.

Data from preclinical studies showed lenalidomide sensitizes myeloma cells to bortezomib and dexamethasone. The results of phase 1 and phase II studies show that this regimen is well tolerated and very active with durable responses seen in patients with heavily pretreated relapsed and/or refractory myeloma, including patients who have had prior lenalidomide, bortezomib, thalidomide and stem cell transplantation. Pending larger study data and peer reviewed publications, bortezomib in combination with lenalidomide/dexamethasone is a category 2B recommendation.

The NCCN myeloma panel members highly encourage enrolling patients in clinical trials.

Adjunctive Treatment

Important advances have been made in adjunctive treatment of patients with multiple myeloma. Additions include a recommendation for HSV prophylaxis in patients receiving bortezomib. In addition, anticoagulant
Multiple Myeloma

Discussion

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

Prophylaxis is recommended for patients receiving thalidomide or lenalidomide in combination with dexamethasone.\(^{48, 120, 121}\)

Bony manifestations of myeloma, in the form of diffuse osteopenia and/or osteolytic lesions, develop in 85% of patients. Related complications are the major cause of limitations in quality of life and performance status in patients with multiple myeloma. A large, double-blind, randomized trial has shown that monthly use of intravenous pamidronate (a bisphosphonate) can decrease pain and bone-related complications, improve performance status, and, importantly, preserve quality of life in patients with Durie-Salmon stage III myeloma and at least one lytic lesion.\(^{122, 123}\) Zoledronic acid is more potent, can be administered more rapidly, and has equivalent benefits.\(^{124}\) Based on published data and clinical experience, the guidelines recommend the use of bisphosphonates for all patients with multiple myeloma who have bone disease, including osteopenia (category 1).\(^{125, 126}\) Results from the study conducted by Zervas et al\(^{127}\) show a 9.5 fold greater risk for the development of osteonecrosis of the jaw with zoledronic acid compared to pamidronate. In light of these data, pamidronate may be preferred over zoledronic acid, until further published data on these adverse effects become available. In 10% to 20% of patients with earlier-stage disease who do not have bone disease, bisphosphonates may be considered but preferably in a clinical trial. An annual skeletal survey is recommended for follow-up of bone disease. Bone densitometry or other metabolic studies should be reserved for clinical trials. Patients who are chronic users of bisphosphonates should have their renal function monitored. They should be monitored for osteonecrosis of the jaw.

Low-dose radiation therapy (10-30 Gy) is used for the palliative treatment of uncontrolled pain, impending pathologic fracture, or impending spinal cord compression.\(^{18}\) Limited involved fields should be used to limit the effect of irradiation on stem cell harvest or its effect on potential future treatments; the radiation doses administered should not preclude stem cell collection in potential candidates for high-dose therapy and hematopoietic SCT. Orthopedic consultation should be obtained for impending or actual fractures in weight-bearing bones, bony compression of the spinal cord, or vertebral column instability. Either vertebroplasty or kyphoplasty should be considered for symptomatic vertebral compression fractures.

Other Complications

Hypercalcemia should be treated with hydration and furosemide, bisphosphonates, steroids, and/or calcitonin. Plasmapheresis should be used as adjunctive therapy for symptomatic hyperviscosity.\(^{128}\) Institutions differ in their use of plasmapheresis for adjunctive treatment of renal dysfunction. Erythropoietin therapy should be considered for anemic patients, especially those with renal failure. Measuring endogenous erythropoietin levels may also be helpful in treatment planning.\(^{129, 130}\) (see NCCN Cancer- and Chemotherapy-Induced Anemia Guidelines). To prevent infection (1) intravenous immunoglobulin therapy should be considered in the setting of recurrent, life-threatening infections; (2) pneumococcal and influenza vaccine should also be considered; and (3) \textit{Pneumocystis carinii} pneumonia (PCP), herpes, and antifungal prophylaxis should also be considered, if a high-dose dexamethasone regimen is used. Bortezomib treatment has been associated with an incidence of herpes zoster.\(^{102, 131}\) Herpes prophylaxis should also be considered in patients receiving bortezomib\(^{36}\) (see NCCN Prevention and Treatment of Cancer-Related Infections Guidelines). Hydration should be maintained and nonsteroidal anti-inflammatory agents (NSAIDs) should be avoided to decrease the chances of renal dysfunction; however, renal dysfunction is not a contraindication for transplant. The use of intravenous contrast media and NSAIDs should also be avoided in patients with renal impairment. Prophylactic anticoagulation should also be considered if a thalidomide-based, or lenalidomide/dexamethasone therapy is used.\(^{48}\)

Systemic Light Chain Amyloidosis
Systemic light chain amyloidosis is characterized by decreased numbers of monoclonal plasma cells in the bone marrow; however, the protein produced by these plasma cells has an affinity for visceral organs (such as kidney, heart, liver, and spleen), and this protein causes related end-organ dysfunction.¹³²

**Workup**

The initial diagnostic workup includes a history and physical examination; evaluation of orthostatic vital signs; CBC with differential and platelets; and blood urea nitrogen content, serum creatinine, and electrolytes. The diagnosis of amyloidosis requires the identification of amyloid deposits in tissues either by aspiration of abdominal subcutaneous fat and biopsy of the organs involved. The characterization of amyloidosis as a systemic light chain type requires the demonstration of the underlying plasma cell clone. Monoclonal plasma cell population can be detected in bone marrow aspirates by immunohistochemical staining of kappa and lambda chains. Screening by serum electrophoresis alone may be inadequate, as it does not show a monoclonal spike in nearly 50% of cases. Therefore, all patients should undergo immunofixation electrophoresis of both serum and urine, which could detect a monoclonal component. The measurement of circulating serum free light chain (FLC) is a useful diagnostic complement. Since the treatment is different in the various types of systemic amyloidosis, genetic testing especially for African-American and peripheral neuropathy patients must be done, to identify the specific mutation in the hereditary forms.

A majority of the patients present with one or more organ damage. Cardiac involvement is diagnosed by echocardiography (EKG), echocardiogram, chest x-ray, and high serum concentration of natriuretic peptide type-B (BNP) and troponin. Liver and gastrointestinal (GI) involvement is diagnosed by elevated serum alkaline phosphatase; performing stool guaiac tests to detect fecal occult blood; gastric emptying scan if gastroparesis is present; ultrasound or CT scan to determine craniocaudal liver span. An electromyogram (EMG) is a test is performed if the patient has significant peripheral neuropathy to confirm peripheral nervous system involvement. Endocrine tests and pulmonary tests may be performed if involvement of endocrine system or lungs is suspected.

**Treatment**

Treatment of systemic light chain amyloidosis should be in a clinical trial because data are insufficient to identify optimal treatment of the underlying plasma cell disorder. Most of the treatment strategies used in systemic light chain amyloidosis are derived from multiple myeloma regimens. Intermediate or high-dose melphalan followed by stem cell transplantation is one of the therapeutic options listed by the NCCN panel. However, this option may not be applicable to all. Patients have to be carefully selected as it is associated with significant treatment-related mortality.¹³³⁻¹³⁵ The extent of organ involvement is considered as predictor of outcome.¹³⁶ In eligible patients, high-dose chemotherapy with peripheral blood stem cell transplantation has been associated with higher response rates higher OS than standard chemotherapy.¹³⁶ Complete response is defined as no evidence of an underlying plasma cell dyscrasia 1 year after treatment. The best outcomes following stem cell transplant have been reported in patients who achieve complete response to high-dose induction chemotherapy ¹³⁷ including improvement of organ-related disease.¹³⁸ The melphalan may be dosed according to risk and toxicity. The reported toxicity of reduced-dose of melphalan is substantially less than high dose.¹³⁹

Melphalan and dexamethasone has also been used in the management of systemic light chain amyloidosis. Promising results have been shown in patients with primary amyloidosis who are ineligible for stem cell transplantation treated with combination of melphalan and high-dose dexamethasone. A hematologic response has been obtained in 67% patients and 33% of patients achieved complete remission.¹⁴⁰
Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

Improvement in organ function was seen in 48% of patients. The updated results reported that survival at 6 years was about 50% and progression free survival was 40%.

Other treatment options include dexamethasone and alpha-interferon. In a multicenter, cooperative group trial (n = 93), complete hematologic response was seen in 24% and improvement of organ dysfunction in 45% of the evaluable patients; overall median survival was 31 months; and 2-year survival rate was 60%.

Thalidomide in combination with dexamethasone was studied in a small group of patients. Only 11 patients out of the 31 enrolled tolerated 400 mg/day of thalidomide for a median of 5.7 months; 20 patients experienced toxicity of grade 3 or more. Therefore, although this combination is active, the associated toxicity is substantial.

Phase II studies have shown lenalidomide in combination with dexamethasone is also active in the treatment of patients with systemic light chain amyloidosis, including those with relapsed/refractory disease. The incidence of dermatologic adverse effects with combination was found to be higher in patients with amyloidosis compared to those with myeloma. In addition, progressive azotemia has also been reported in patients with amyloidosis, warranting careful monitoring of patients on this regimen.

Clinical studies have shown that bortezomib with or without dexamethasone is active in both untreated and relapsed amyloidosis.

Wechalekar et al used oral regimen of cyclophosphamide, thalidomide, and dexamethasone (CTD) or a risk attenuated regimen CTDa in phase II study involving 75 patients with advanced AL amyloidosis, including 44 patients with clonal relapse after prior therapy. Fifty-one (68%) patients received CTD and 24 (32%) received CTDa. The study reported overall hematologic response in 48 (74%) of 65 evaluable patients, including complete responses in 14 (21%) and partial responses in 34 (53%) cases. Median estimated OS from commencement of treatment was 41 months. Three-year estimated OS was 100% and 82% among patients with complete and partial hematologic response respectively. Treatment was discontinued in 8% of the patients due to toxicities. Grade 2 toxicities were seen in 52% of patients. Treatment related mortality was 4%.

Based on the evidence discussed above, the current NCCN guidelines list the following as therapeutic considerations for management of patients with systemic light chain amyloidosis (all category 2A recommendation): intermediate or high-dose melphalan followed by stem cell transplantation; oral melphalan and dexamethasone; dexamethasone in combination with alpha-interferon; thalidomide-, lenalidomide-, or bortezomib in combination with dexamethasone; single agent bortezomib; and CTD regimen.

The treatment options are listed alphabetically in the NCCN guidelines and do not indicate or imply preference. As the optimal therapy for systemic light chain amyloidosis still remains unknown, the NCCN panel members strongly encourage treatment in the context of clinical trial when possible.
Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011

References


Multiple Myeloma Discussion

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011


### Multiple Myeloma

**Discussion**

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011


42. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone...


56. San Miguel JF, Schlag R, Khugava NK, et al. Bortezomib plus...
Multiple Myeloma

Discussion

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011


62. Roy V, Stewart AK, Bergsagel PL, et al. Phase II study of melphalan, prednisone and lenalidomide combination for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation. ASH Annual Meeting Abstracts 2008;112:Abstract 2769. Available at http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;112/11/2769


79. Goldschmidt H. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial Haematologica 2005;90(s1):Abstract 38 Available at Not Available


Discussion

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011


Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011


100. Mateos M-V, Oriol A, Martinez J, et al. A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years. ASH Annual Meeting Abstracts 2009;114:3. Available at http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/3


Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011


Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011


139. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow...
Multiple Myeloma
Discussion
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 1.2011


